MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy

Purpose Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy. Methods We r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Applied Clinical Medical Physics 2024-03, Vol.25 (3), p.e14293-n/a
Hauptverfasser: Gumus, Kazim Z., Contreras, Samuel Serrano, Al‐Toubat, Mohammed, Harmon, Ira, Hernandez, Mauricio, Ozdemir, Savas, Kumar, Sindhu, Yuruk, Nurcan, Mete, Mutlu, Balaji, K. C., Bandyk, Mark, Gopireddy, Dheeraj R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 3
container_start_page e14293
container_title Journal of Applied Clinical Medical Physics
container_volume 25
creator Gumus, Kazim Z.
Contreras, Samuel Serrano
Al‐Toubat, Mohammed
Harmon, Ira
Hernandez, Mauricio
Ozdemir, Savas
Kumar, Sindhu
Yuruk, Nurcan
Mete, Mutlu
Balaji, K. C.
Bandyk, Mark
Gopireddy, Dheeraj R.
description Purpose Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy. Methods We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi‐parametric MRI (mpMRI) images post‐proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2‐weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross‐Validation method (RFE‐CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12‐core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators. Results Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi‐class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72–1.00] in differentiating cancer from the benign and healthy tissues. Conclusions Our proof‐of‐concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.
doi_str_mv 10.1002/acm2.14293
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A796754946</galeid><sourcerecordid>A796754946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5163-58effabe1de6e5dd94ef30e7a7d43e834b68f7a52e113757aa698a956774b0593</originalsourceid><addsrcrecordid>eNp9kd1qFDEUxwdRbK3e-AAy4I0Iu-ZzMrmSZfGj0CKIXoczmZNtyuxkzcxU9s5H6DP2STzbqaV6IYHk5OSX__kqipecLTlj4h34rVhyJax8VBxzLaqFtVw9fmAfFc-G4ZIxzmtZPy2OZK2YtcocF-H86-nNr-sGBmzLDG1M2-jLgDBOGYcypFzGFvsxhn3sN2VGP-VM93KX0zDCiKWH3mMuIYy0k3dM_a0QjJGs8QIz7PbPiycBugFf3J0nxfePH76tPy_Ovnw6Xa_OFl7zSi50jSFAg7zFCnXbWoVBMjRgWiWxlqqp6mBAC-RcGm0AKluD1ZUxqmHaypPi_ay7m5ottp4yzdC5XY5byHuXILq_X_p44TbpynFmJfVHkMKbO4Wcfkw4jG4bB49dBz2maXDUZaGkFLoi9PU_6GWack_1EaW1FJWUmqjlTG2gQxf7kCiwp9UitTr1GCL5V8ZWRiurDrJv5w-eWjxkDPfpc-YOA3eHgbvbgRP86mHB9-ifCRPAZ-Anhdn_R8qt1udiFv0NMni35w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2955326335</pqid></control><display><type>article</type><title>MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Gumus, Kazim Z. ; Contreras, Samuel Serrano ; Al‐Toubat, Mohammed ; Harmon, Ira ; Hernandez, Mauricio ; Ozdemir, Savas ; Kumar, Sindhu ; Yuruk, Nurcan ; Mete, Mutlu ; Balaji, K. C. ; Bandyk, Mark ; Gopireddy, Dheeraj R.</creator><creatorcontrib>Gumus, Kazim Z. ; Contreras, Samuel Serrano ; Al‐Toubat, Mohammed ; Harmon, Ira ; Hernandez, Mauricio ; Ozdemir, Savas ; Kumar, Sindhu ; Yuruk, Nurcan ; Mete, Mutlu ; Balaji, K. C. ; Bandyk, Mark ; Gopireddy, Dheeraj R.</creatorcontrib><description>Purpose Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy. Methods We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi‐parametric MRI (mpMRI) images post‐proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2‐weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross‐Validation method (RFE‐CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12‐core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators. Results Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi‐class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72–1.00] in differentiating cancer from the benign and healthy tissues. Conclusions Our proof‐of‐concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.</description><identifier>ISSN: 1526-9914</identifier><identifier>EISSN: 1526-9914</identifier><identifier>DOI: 10.1002/acm2.14293</identifier><identifier>PMID: 38409947</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Biopsy ; Cancer ; Cancer therapies ; Care and treatment ; Diseases ; Feature selection ; Health aspects ; Magnetic resonance imaging ; Medical Imaging ; Medical imaging equipment ; Medical research ; Medicine, Experimental ; MRI ; Neural networks ; Patients ; Prostate cancer ; proton therapy ; Radiation therapy ; Radiomics ; Radiotherapy ; recurrence ; Relapse ; Support vector machines ; Tumors</subject><ispartof>Journal of Applied Clinical Medical Physics, 2024-03, Vol.25 (3), p.e14293-n/a</ispartof><rights>2024 The Authors. is published by Wiley Periodicals, Inc. on behalf of The American Association of Physicists in Medicine.</rights><rights>2024 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.</rights><rights>COPYRIGHT 2024 John Wiley &amp; Sons, Inc.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5163-58effabe1de6e5dd94ef30e7a7d43e834b68f7a52e113757aa698a956774b0593</citedby><cites>FETCH-LOGICAL-c5163-58effabe1de6e5dd94ef30e7a7d43e834b68f7a52e113757aa698a956774b0593</cites><orcidid>0000-0002-1450-6868</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930012/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930012/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,1419,11569,27931,27932,45581,45582,46059,46483,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38409947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gumus, Kazim Z.</creatorcontrib><creatorcontrib>Contreras, Samuel Serrano</creatorcontrib><creatorcontrib>Al‐Toubat, Mohammed</creatorcontrib><creatorcontrib>Harmon, Ira</creatorcontrib><creatorcontrib>Hernandez, Mauricio</creatorcontrib><creatorcontrib>Ozdemir, Savas</creatorcontrib><creatorcontrib>Kumar, Sindhu</creatorcontrib><creatorcontrib>Yuruk, Nurcan</creatorcontrib><creatorcontrib>Mete, Mutlu</creatorcontrib><creatorcontrib>Balaji, K. C.</creatorcontrib><creatorcontrib>Bandyk, Mark</creatorcontrib><creatorcontrib>Gopireddy, Dheeraj R.</creatorcontrib><title>MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy</title><title>Journal of Applied Clinical Medical Physics</title><addtitle>J Appl Clin Med Phys</addtitle><description>Purpose Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy. Methods We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi‐parametric MRI (mpMRI) images post‐proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2‐weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross‐Validation method (RFE‐CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12‐core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators. Results Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi‐class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72–1.00] in differentiating cancer from the benign and healthy tissues. Conclusions Our proof‐of‐concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.</description><subject>Biopsy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Diseases</subject><subject>Feature selection</subject><subject>Health aspects</subject><subject>Magnetic resonance imaging</subject><subject>Medical Imaging</subject><subject>Medical imaging equipment</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>MRI</subject><subject>Neural networks</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>proton therapy</subject><subject>Radiation therapy</subject><subject>Radiomics</subject><subject>Radiotherapy</subject><subject>recurrence</subject><subject>Relapse</subject><subject>Support vector machines</subject><subject>Tumors</subject><issn>1526-9914</issn><issn>1526-9914</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kd1qFDEUxwdRbK3e-AAy4I0Iu-ZzMrmSZfGj0CKIXoczmZNtyuxkzcxU9s5H6DP2STzbqaV6IYHk5OSX__kqipecLTlj4h34rVhyJax8VBxzLaqFtVw9fmAfFc-G4ZIxzmtZPy2OZK2YtcocF-H86-nNr-sGBmzLDG1M2-jLgDBOGYcypFzGFvsxhn3sN2VGP-VM93KX0zDCiKWH3mMuIYy0k3dM_a0QjJGs8QIz7PbPiycBugFf3J0nxfePH76tPy_Ovnw6Xa_OFl7zSi50jSFAg7zFCnXbWoVBMjRgWiWxlqqp6mBAC-RcGm0AKluD1ZUxqmHaypPi_ay7m5ottp4yzdC5XY5byHuXILq_X_p44TbpynFmJfVHkMKbO4Wcfkw4jG4bB49dBz2maXDUZaGkFLoi9PU_6GWack_1EaW1FJWUmqjlTG2gQxf7kCiwp9UitTr1GCL5V8ZWRiurDrJv5w-eWjxkDPfpc-YOA3eHgbvbgRP86mHB9-ifCRPAZ-Anhdn_R8qt1udiFv0NMni35w</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Gumus, Kazim Z.</creator><creator>Contreras, Samuel Serrano</creator><creator>Al‐Toubat, Mohammed</creator><creator>Harmon, Ira</creator><creator>Hernandez, Mauricio</creator><creator>Ozdemir, Savas</creator><creator>Kumar, Sindhu</creator><creator>Yuruk, Nurcan</creator><creator>Mete, Mutlu</creator><creator>Balaji, K. C.</creator><creator>Bandyk, Mark</creator><creator>Gopireddy, Dheeraj R.</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1450-6868</orcidid></search><sort><creationdate>202403</creationdate><title>MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy</title><author>Gumus, Kazim Z. ; Contreras, Samuel Serrano ; Al‐Toubat, Mohammed ; Harmon, Ira ; Hernandez, Mauricio ; Ozdemir, Savas ; Kumar, Sindhu ; Yuruk, Nurcan ; Mete, Mutlu ; Balaji, K. C. ; Bandyk, Mark ; Gopireddy, Dheeraj R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5163-58effabe1de6e5dd94ef30e7a7d43e834b68f7a52e113757aa698a956774b0593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biopsy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Diseases</topic><topic>Feature selection</topic><topic>Health aspects</topic><topic>Magnetic resonance imaging</topic><topic>Medical Imaging</topic><topic>Medical imaging equipment</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>MRI</topic><topic>Neural networks</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>proton therapy</topic><topic>Radiation therapy</topic><topic>Radiomics</topic><topic>Radiotherapy</topic><topic>recurrence</topic><topic>Relapse</topic><topic>Support vector machines</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gumus, Kazim Z.</creatorcontrib><creatorcontrib>Contreras, Samuel Serrano</creatorcontrib><creatorcontrib>Al‐Toubat, Mohammed</creatorcontrib><creatorcontrib>Harmon, Ira</creatorcontrib><creatorcontrib>Hernandez, Mauricio</creatorcontrib><creatorcontrib>Ozdemir, Savas</creatorcontrib><creatorcontrib>Kumar, Sindhu</creatorcontrib><creatorcontrib>Yuruk, Nurcan</creatorcontrib><creatorcontrib>Mete, Mutlu</creatorcontrib><creatorcontrib>Balaji, K. C.</creatorcontrib><creatorcontrib>Bandyk, Mark</creatorcontrib><creatorcontrib>Gopireddy, Dheeraj R.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Applied Clinical Medical Physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gumus, Kazim Z.</au><au>Contreras, Samuel Serrano</au><au>Al‐Toubat, Mohammed</au><au>Harmon, Ira</au><au>Hernandez, Mauricio</au><au>Ozdemir, Savas</au><au>Kumar, Sindhu</au><au>Yuruk, Nurcan</au><au>Mete, Mutlu</au><au>Balaji, K. C.</au><au>Bandyk, Mark</au><au>Gopireddy, Dheeraj R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy</atitle><jtitle>Journal of Applied Clinical Medical Physics</jtitle><addtitle>J Appl Clin Med Phys</addtitle><date>2024-03</date><risdate>2024</risdate><volume>25</volume><issue>3</issue><spage>e14293</spage><epage>n/a</epage><pages>e14293-n/a</pages><issn>1526-9914</issn><eissn>1526-9914</eissn><abstract>Purpose Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy. Methods We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi‐parametric MRI (mpMRI) images post‐proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2‐weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross‐Validation method (RFE‐CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12‐core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators. Results Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi‐class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72–1.00] in differentiating cancer from the benign and healthy tissues. Conclusions Our proof‐of‐concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>38409947</pmid><doi>10.1002/acm2.14293</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1450-6868</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1526-9914
ispartof Journal of Applied Clinical Medical Physics, 2024-03, Vol.25 (3), p.e14293-n/a
issn 1526-9914
1526-9914
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930012
source DOAJ Directory of Open Access Journals; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central
subjects Biopsy
Cancer
Cancer therapies
Care and treatment
Diseases
Feature selection
Health aspects
Magnetic resonance imaging
Medical Imaging
Medical imaging equipment
Medical research
Medicine, Experimental
MRI
Neural networks
Patients
Prostate cancer
proton therapy
Radiation therapy
Radiomics
Radiotherapy
recurrence
Relapse
Support vector machines
Tumors
title MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T11%3A57%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MRI%E2%80%90based%20radiomic%20features%20for%20identifying%20recurrent%20prostate%20cancer%20after%20proton%20radiation%20therapy&rft.jtitle=Journal%20of%20Applied%20Clinical%20Medical%20Physics&rft.au=Gumus,%20Kazim%20Z.&rft.date=2024-03&rft.volume=25&rft.issue=3&rft.spage=e14293&rft.epage=n/a&rft.pages=e14293-n/a&rft.issn=1526-9914&rft.eissn=1526-9914&rft_id=info:doi/10.1002/acm2.14293&rft_dat=%3Cgale_pubme%3EA796754946%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2955326335&rft_id=info:pmid/38409947&rft_galeid=A796754946&rfr_iscdi=true